Search 

Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.

U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).

We facilitate the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships

We facilitate the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships

At MTAnalyics we focus on increasing statistical power to improve the detection of weak association signals between variables. By contrast to data mining, we are using statistical tools that allow us to provide power and p-values in our analysis. In other words, we are specific alike classic statistics and sensitive as data mining.

For clinical trials, we significantly reduce the sample size while keeping the same power. Fundamentally, you will be able to decrease your sample size by 30% while keeping the same p-value, the same statistical power. Obvious main consequences: gain of time, of money, resources etc…

Our work addresses these challenges and aims at providing rationale to design and perform statistical analysis when large amount of data are available. We are not competing with the companies allowing to hire patients faster. We come into play before the design of the trial even started to allow for the design of a trial to include a reduced sample size. We focus in particular on increasing statistical power in order to reduce sample size or improving the detection of weak association between variables by leveraging all available information.

In big data, we provide insights into data sets, predict outcomes, increase the strengths of the models used to explain an outcome based on the analysis of a dataset. Again, the basis of our approach is to improve the detection of weak signals.

Any classical approach is able to detect a strong signal, but when an outcome is not explained (or associated) to one major or a few big variables but by a multiple of weak signals, you need a model to link and find these weak signals, in order to explain a maximum of your outcome.

With our approach, we are able to explain significantly more of the outcome, by reinforcing the models, by finding weak associations hidden in the data sets and missed by the other approaches. In other words, we detect associations that others cannot.

AGuIX is a Gadolinium nanoparticle, injectable by IV, that improve MRI-guided radiation therapy, allowing personalized medicine for an optimize radiation treatment. Eliminated by the kidneys without toxicity, AGuIX allow within a single injection tumor delineation and enhancement of treatment efficacy.

Radiation therapy can generates toxicity in the organs surrounding the tumor and CT images are not specific in soft tissue areas. AGuIX enhance the tumor delineation under MRI by enhancing the contrast and boost the effect of the radiation in the tumor. AGuIX can enhance treatment efficacy and might be use to reduce the planned dose to spare the healthy organs.

1/ Radiation Oncology 2/ Contrast Agent 3/ Compagnon diagnosis

1/ Radiosensitizer 2/ MRI agent 3/ Personalized medicine / Various injection mode

Biomedical research is gravitating towards 3D cell culture models and tissue printing. At n3D, we sell kits and services for 3D cell culture. Our core technology is the magnetization of cells, which can then be directed using magnetic forces. In this manner, we can either levitate or bioprint cells. These cultures are faster to assemble than other systems and easier to handle with magnets without losing samples. Check out our products and ourservices for more information on our technology, and how we can help you!

Nanotech Plus, LLC is a consulting firm focused on the commercialization of advanced materials. Our clients include Fortune 500 companies to startups as well as government agencies. Whether you need information ranging from a potential market for a new product to an assessment of a patent portfolio, we can help. In our 5 year history, we have had a diverse group of clients with a diverse set of needs- but we've been able to satisfy them all.

consulting, marketing patent assessment, due diligence

Our mission is to help create the next generation of powerhouse biotech companies by providing entrepreneurs and innovative life-sciences startups with the space and resources they need to test out, challenge, and nurture early ideas. In order to create a fertile environment in which visionaries can thrive, we aim to:

• Foster a collaborative atmosphere that allows thought-sharing and creative exchange

• Offer best-in-class infrastructure to enable the unfettered practice of science

• Promote cost efficiencies through sharing of many services such as permitting, purchasing, maintenance, IT, and security

• Anticipate needs and roadblocks for entrepreneurs in order to provide the smoothest possible path to growth

• Create a bioinnovation ecosystem that fosters collegial interactions among industry, investors, government, and academia